Ropanicant

DRUG2 trials

Sponsors

Suven Life Sciences Limited

Conditions

Major Depressive DisorderMajor Depressive Disorder (MDD)

Phase 2

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

CompletedNCT06126497

Suven Life Sciences LimitedMajor Depressive Disorder

Start: 2024-02-05End: 2024-07-19Updated: 2026-09-01

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

CompletedNCT06836063

Suven Life Sciences LimitedMajor Depressive Disorder (MDD)

Start: 2025-07-15End: 2026-02-23Updated: 2026-04-07